[1]刘建平,何建峰.黄芪甲苷对大鼠肺缺血再灌注损伤的保护作用及其机制研究[J].西部中医药,2018,31(02):21-25.
　LIU Jianping,HE Jianfeng.Study on the Protective Effects of Astragaloside IV to the Rats Suffering from Lung Ischemical Reperfusion Injury and Its Mechanism[J].Western Journal of Traditional Chinese Medicine,2018,31(02):21-25.
点击复制

黄芪甲苷对大鼠肺缺血再灌注损伤的保护作用及其机制研究()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
31
期数:
2018年02期
页码:
21-25
栏目:
出版日期:
2018-02-15

文章信息/Info

Title:
Study on the Protective Effects of Astragaloside IV to the Rats Suffering from Lung Ischemical Reperfusion Injury and Its Mechanism
文章编号:
1004-6852(2018)02-0021-05
作者:
刘建平，何建峰
邯郸市中医院，河北 邯郸 056001
Author(s):
LIU Jianping, HE Jianfeng
Handan Municipality TCM Hospital, Handan 056001, China
关键词:
黄芪甲苷; 肺组织; 缺血再灌注; 保护; 机制; 动物实验; 大鼠
Keywords:
astragaloside IV;  lung tissue;  ischemical reperfusion;  protection;  mechanism;  animal experiment;  the rats
分类号:
R322.3+5
文献标志码:
A
摘要:
目的：研究黄芪甲苷对大鼠肺缺血再灌注损伤的保护作用及其机制。方法：将50只实验用大鼠随机分为假手术组、模型组和黄芪甲苷(20、40、80 mg/kg)组，每组10只；采用夹闭左肺门45分钟后松夹的方法制备肺缺血再灌注损伤大鼠模型，各组分别于术前30分钟腹腔注射给药。再灌注2 小时后，测定肺组织湿/干重比(W/D)，测定肺组织中抗氧化酶(SOD、GSH-Px、CAT)活性和血清中髓过氧化物酶(MPO)活性、丙二醛(MDA)含量，HE染色法观察肺组织形态结构变化；TUNEL法观察肺组织细胞凋亡状况并计算凋亡指数(Apoptosis Index，AI)。结果：与模型组比较，黄芪甲苷(40、80 mg/kg)组肺组织W/D显著降低，肺组织中SOD、GSH-Px、CAT活性显著升高，血清中MPO活性和MDA含量显著降低，肺组织形态结构变化和肺细胞病变显著减轻，肺细胞凋亡状况明显改善，黄芪甲苷(40、80 mg/kg)组AI显著降低，上述差异均具有统计学意义(P＜0.05)。结论：黄芪甲苷对肺缺血再灌注损伤大鼠具有保护作用，作用机制可能与黄芪甲苷能够有效改善抗氧化酶活性、降低氧化应激损伤、减轻肺水肿、抑制细胞凋亡有关。
Abstract:
Objective: To study the protective effects and the mechanism of astragaloside IV to the rats with lung ischemical reperfusion injury. Methods: Fifty rats were randomized into sham operation group, the model group and astragaloside IV groups (20, 40 and 80 mg/kg), ten rats each group, the rat model was prepared by Hilum occlusion of left lung for 45 minutes and loosening, different groups were medicated by intraperitoneal injection 30 minutes ago before the surgery. After reperfusion for two hours, lung wet/dry weight ratio (W/D) was detected, the contents of MDA, the activity of MPO in the serum, the activity of SOD, GSH-Px and CAT in lung tissue were detected, morphological changes of lung tissue were observed by HE staining method, cellular apoptosis conditions of lung tissue was observed by TUNEL method and apoptosis index(AI) was calculated. Results: Compared with the model group, lung W/D notably decreased in astragaloside IV groups (40 and 80 mg/kg), the activity of SOD, GSH-Px and CAT in lung tissue raised significantly, the activity of MPO and the contents of MDA in the serum lowered significantly, morphological changes of lung and lung cytopathy alleviated significantly, lung cellular apoptosis conditions improved notably, AI decreased notably in astragaloside IV groups (40 and 80 mg/kg), and the difference all above had statistical meaning (P＜0.05). Conclusion: Astragaloside IV shows protective effects to the rats with lung ischemical reperfusion injury, and its mechanism might be related to that astragaloside IV could effectively improve the activity of antioxidase, decrease oxidative stress injury, relieve pulmonary edema and inhibit cellular apoptosis.

相似文献/References:

[1]吴忠民,贾 忠△,李喜香,等.黄芪党参颗粒中黄芪甲苷含量的HPLC测定方法[J].西部中医药,2012,25(10):23.
　WU Zhong-min,JIA Zhong,LI Xi-xiang,et al.HPLC Determination of Astragaloside Ⅳ in HuangQi DangShen Granule[J].Western Journal of Traditional Chinese Medicine,2012,25(02):23.
[2]李红,王胜,沈明霞,等.黄芪甲苷对特发性肺纤维化模型大鼠肺组织碱性成纤维细胞生长因子(bFGF)表达的影响[J].西部中医药,2015,28(12):21.
[3]李红,沈明霞,谢海彬,等.黄芪甲苷对特发性肺纤维化模型大鼠肺组织CD34表达的影响[J].西部中医药,2015,28(09):6.
[4]李彩东,王信,张伟.参芪心舒胶囊中黄芪甲苷、芍药苷和丹参酮ⅡA含量的测定*[J].西部中医药,2013,26(10):17.
　LI Caidong,WANG Xin,ZHANG Wei.Assaying of Astragaloside Ⅳ, Peoniflorin and TanshinoneⅡA in ShenQi XinShu Capsule[J].Western Journal of Traditional Chinese Medicine,2013,26(02):17.
[5]刘世军,赵海峰,唐志书△,等.正交设计法优选补阳还五胶囊提取工艺[J].西部中医药,2016,29(04):32.
　LIU Shijun,,et al.Optimization of Extraction Process of BuYang HuanWu Capsules by Orthogonal Design[J].Western Journal of Traditional Chinese Medicine,2016,29(02):32.
[6]刘世军,赵海峰,唐志书,等.薄层扫描法测定补阳还五胶囊黄芪甲苷的含量[J].西部中医药,2016,29(01):30.
　LIU Shijun,ZHAO Haifeng,TANG Zhishu,et al.Determination of Astragaloside Ⅳ in BuYang HuanWu Capsules by TLC[J].Western Journal of Traditional Chinese Medicine,2016,29(02):30.
[7]王晓琳,张平.黄芪饮片与黄芪配方颗粒有效成分含量比较[J].西部中医药,2017,30(02):25.
　WANG Xiaolin,ZHANG Ping.Comparsion of Effective Elements Contents between Slices of Prepared HuangQi and Formula Granules of HuangQi[J].Western Journal of Traditional Chinese Medicine,2017,30(02):25.
[8]武向丽.黄芪甲苷对实验性糖尿病大鼠睾丸组织的保护作用[J].西部中医药,2017,30(11):32.
　WU Xiangli.The Protective Effects of Astragalosides IV on Testicular Tissue of Experimental Diabetic Rats[J].Western Journal of Traditional Chinese Medicine,2017,30(02):32.
[9]隋晓丽,张红艳,田晓倩,等.肺抑瘤合剂质量标准研究[J].西部中医药,2018,31(09):46.
　SUI Xiaoli,ZHANG Hongyan,TIAN Xiaoqian,et al.Study on Quality Standard of Pulmonary Tumor-inhibiting Mixture[J].Western Journal of Traditional Chinese Medicine,2018,31(02):46.
[10]杨长花,程芬,李慧,等.4个主要黄芪产地黄芪质量比较[J].西部中医药,2019,32(01):27.
　YANG Changhua,CHENG Fen,LI Hui,et al.Quality Comparisons of HuangQi Collected from Four Major Producing Areas[J].Western Journal of Traditional Chinese Medicine,2019,32(02):27.

备注/Memo

备注/Memo:
收稿日期：2017-04-16 作者简介：刘建平(1977—)，男，主管药师。研究方向：药学研究。
更新日期/Last Update: 2018-02-15